8 February 2013

Angel Biotechnology Holdings plc

("Angel" or "the Company")

Statement regarding suspension

On 28 January 2013, the Company advised announced that Company needed to enter into a strategic relationship with another party to develop more effectively its contract manufacturing business and that it had for some time been in discussions with a consortium of overseas organisations in this connection. The Company also stated that in the opinion of the Board, this arrangement was  essential to the ongoing viability of the Company.

The Company regrets to announce that discussions with that consortium have been terminated and requested an immediate suspension of trading in its Ordinary Shares on AIM pending clarification of its financial position.

In view of its trading difficulties, the Company intends to appoint administrators and a further announcement will be made as appropriate.

For further information:

Angel Biotechnology Holdings plc                                                                                                                       

Nicholas Smith, Non-Executive Chairman                                                                 +44 (0) 131 445 6077

                                                                                                                                                     www.angelbio.com

Grant Thornton, Corporate Finance

Colin Aaronson / Melanie Frean                                                                                    +44 (0) 20 7383 5100